Articles de revue sur le cancer colorectal - Derniè res parutions

InTextoResearch, agence d'information scientifique


InTextoResearch vous informe sur les dernières parutions d'articles de
revue sur le cancer colorectal (24 mai 2008):


Progress and challenges in the adjuvant treatment of stage II and III
colon cancers.
Chua YJ, Zalcberg JR.
Expert Rev Anticancer Ther. 2008 Apr;8(4):595-604.

Immune cells in colorectal cancer: prognostic relevance and
therapeutic strategies.
Atreya I, Neurath MF.
Expert Rev Anticancer Ther. 2008 Apr;8(4):561-72.

A retrospective on the inhibition of epidermal growth factor receptor
as a therapeutic strategy for patients with relapsed metastatic
colorectal cancer: impact on treatment of today's patients.
Jackson C, Cunningham D.
Clin Colorectal Cancer. 2007 Dec;7 Suppl 1:S8-15.

Exploring alternative individualized treatment strategies in
colorectal cancer.
Wilson PM, Ladner RD, Lenz HJ.
Clin Colorectal Cancer. 2007 Dec;7 Suppl 1:S28-36.

Update on clinical data with regimens inhibiting angiogenesis and
epidermal growth factor receptor for patients with newly diagnosed
metastatic colorectal cancer.
Cohen DJ, Hochster HS.
Clin Colorectal Cancer. 2007 Dec;7 Suppl 1:S21-7.

Update on clinical data combining capecitabine with targeted agents in
newly diagnosed colorectal cancer.
Lee JJ, Chu E.
Clin Colorectal Cancer. 2007 Dec;7 Suppl 1:S16-20.

Hypersensitivity reactions to oxaliplatin and other antineoplastic
agents.
Syrigou E, Syrigos K, Saif MW.
Curr Allergy Asthma Rep. 2008 Mar;8(1):56-62.

Pharmacogenomics in gastrointestinal disorders.
Camilleri M, Saito YA.
Methods Mol Biol. 2008;448:395-412.

Yttrium 90 microsphere selective internal radiation treatment of
hepatic colorectal metastases.
Price TJ, Townsend A.
Arch Surg. 2008 Mar;143(3):313-4.

EGFR antagonists in cancer treatment.
Ciardiello F, Tortora G.
N Engl J Med. 2008 Mar 13;358(11):1160-74.

Colon cancer stem cells.
Ricci-Vitiani L, Pagliuca A, Palio E, Zeuner A, De Maria R.
Gut. 2008 Apr;57(4):538-48.

Novel targets for systemic therapy of colorectal cancer.
Kopetz S.
Clin Adv Hematol Oncol. 2008 Jan;6(1):38-40.

Administration of cetuximab every 2 weeks in the treatment of
metastatic colorectal cancer: an effective, more convenient
alternative to weekly administration?
Tabernero J, Pfeiffer P, Cervantes A.
Oncologist. 2008 Feb;13(2):113-9.

Genetics, clinical manifestations and management of FAP and HNPCC.
Pavlovic-Calic N, Muminhodzic K, Zildzic M, Smajic M, Gegic A,
Alibegovic E, Salkic N, Jovanovic P, Basic M, Iljazovic S.
Med Arh. 2007;61(4):256-9.

Clear cell adenocarcinoma of the colon: a case report and review of
literature.
Soga K, Konishi H, Tatsumi N, Konishi C, Nakano K, Wakabayashi N,
Mitsufuji S, Kataoka K, Okanoue T, Mukaisho K, Hattori T.
World J Gastroenterol. 2008 Feb 21;14(7):1137-40.

Second-line management of metastatic colorectal cancer.
Gallagher DJ, Kemeny N.
Clin Colorectal Cancer. 2008 Jan;7(1):25-32.

Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan
in the first-line treatment of metastatic colorectal cancer.
Masi G, Vasile E, Loupakis F, Bursi S, Ricci S, Petrini I, Fontana A,
Allegrini G, Falcone A.
Clin Colorectal Cancer. 2008 Jan;7(1):7-14.

Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A, Gallego-Plazas J, Guillén-Ponce C.
Expert Rev Anticancer Ther. 2008 Feb;8(2):161-74.

Netrins and their receptors.
Moore SW, Tessier-Lavigne M, Kennedy TE.
Adv Exp Med Biol. 2007;621:17-31.

Synergy between cetuximab and chemotherapy in tumors of the
gastrointestinal tract.
Mahtani RL, Macdonald JS.
Oncologist. 2008 Jan;13(1):39-50.

Convergence of genetic, nutritional and inflammatory factors in
gastrointestinal cancers.
MacFarlane AJ, Stover PJ.
Nutr Rev. 2007 Dec;65(12 Pt 2):S157-66.



(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scimedweb@mail.com)